Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Healthcare systems are increasingly under pressure to provide funding for innovative technologies. These technologies tend to be characterized by their potential to make valued contributions to patient health in areas of relative unmet need, and have high acquisition costs and uncertainty within the evidence base on their actual impact on health. Decision makers are increasingly interested in linking reimbursement strategies to the degree of uncertainty in the evidence base and, as a result, reimbursement for innovative technologies is frequently linked to some form of patient access or risk-sharing scheme. As the dominant methods of economic evaluation report final outcomes only at the time horizon of the analysis, they present only aggregated information. This omits much of the information available on how net benefit is distributed within the time horizon. In this article, we introduce the Net Benefit Probability Map (NBPM), which maps net health benefit versus time to identify how certain decision makers can be about the benefit of technologies at multiple time points. Using an illustrative example, we show how the NBPM can inform decision makers about how long it will take for innovative technologies to ‘pay off’, how methodological choices on discount rates affect results and how alternative payment mechanisms can reduce the risk for decision makers facing innovative technologies.
- Van Hout B, Al J, Gordon G, Rutten F. Costs, effects and C/E ratios alongside a clinical trial. Health Econ. 1994;3(5):309–19. CrossRef
- Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
- Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87. CrossRef
- Eckermann S, Willan A. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. Pharmacoeconomics. 2011;29(7):563–77.
- NICE. Appraising treatments which may extend life, at the end of life. National Institute of Health and Clinical Excellence. 2011. http://www.nice.org.uk/aboutnice/howwework/devnicetech/endoflifetreatments.jsp. Accessed 15th November 2012.
- Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, McKenna C, et al. Uncertainty, evidence and irrecoverable costs: informing approval, pricing and research decisions for health. Centre for Health Economics Research Paper 69. York: University of York; 2011.
- Stafinski T, McCabe C, Menon D. Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into health care systems. Pharmacoeconomics. 2010;28(2):113–42. CrossRef
- NICE. NICE Patient Access Schemes Liaison Unit. 2011. http://www.nice.org.uk/aboutnice/howwework/paslu/patientaccessschemesliaisonunit.jsp. Accessed September 2012.
- Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study of the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment Programme. Health Technol Assess. 2004;8(31):1–103.
- Hall P, Edlin R, Kharroubi S, Gregory W, McCabe C. Expected net present value of information: from burden to investment. Med Decis Mak. 2012;32(3):E11–21. CrossRef
- Hall P, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron D. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering long-term toxicity and patterns of recurrence. Pharmacoeconomics. 2011;29(5):415–32. CrossRef
- Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost effectiveness analysis. Med Decis Mak. 1998;18(2):S68–90. CrossRef
- Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A. Discounting and decision making in the economic evaluation of health-care technologies. Health Econ. 2010;20:2–15.
- Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9. CrossRef
- McCabe C, Edlin R, Stafinski T, Menon D. Access with evidence development schemes: a framework for design and evaluation. Pharmacoeconomics. 2010;28(2):143–52. CrossRef
- Brouwer W, Niessen L, Postma M, Rutten F. Need for differential discounting of costs and health effects in cost effectiveness analyses. Br Med J. 2005;331:446–8. CrossRef
- Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and cost-effectiveness in NICE: stepping back to sort out a confusion. Health Econ. 2006;15(1):1–4. CrossRef
- Jonsson P, Roberts J. Briefing paper for the methods review group working party on discounting. London: National Institute for Health and Clinical Excellence; 2011.
- NICE Citizens Council. How should NICE assess future costs and benefits? http://www.nice.org.uk/media/06B/B8/Citizens_Council_report_on_Discounting.pdf (2011). Accessed 15th November 2012.
- Claxton K, Briggs A, Buxton M, Culyer A, McCabe C, Walker S, et al. Value based pricing for NHS drugs: an opportunity not to be missed? Br Med J. 2008;336(7638):251–4. CrossRef
- O’Brien B, Briggs A. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002;11(6):455–68. CrossRef
- NICE. Guide to the methods of health technology. London: National Institute for Health and Clinical Excellence; 2008.
- Huseraeu DF, Augustovski F, Briggs AH, Carswell C, Drummond M, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): exploration and elaboration. An ISPOR Task Force Report [draft]. http://www.ispor.org/taskforces/documents/ISPOR-Health-Econ-Eval-Pub-Guidelines-CHEERS-draft-for-review.pdf. Accessed 24th June 2013.
- NICE Patient Access Scheme Liaison Unit. http://www.nice.org.uk/aboutnice/howwework/paslu/patientaccessschemesliaisonunit.jsp. Accessed 24th June 2013.
- Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?
Volume 31, Issue 9 , pp 731-737
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Capital Health Endowed Chair in Emergency Medicine Research, Faculty of Medicine & Dentistry, School of Community Based Medicine, University of Alberta, Suite 736, University Terrace, 8303 112th Street, Edmonton, AB, T6G 2M8, Canada
- 2. School of Population Health, University of Auckland, Auckland, New Zealand
- 3. Academic Unit of Health Economics, University of Leeds, Leeds, UK